Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA…
Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and…
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company's singular mission is…
Nephros is a commercial stage medical device company that develops and sells high-performance liquid purification filters. Nephros filters capture contaminants as…
BSIM's mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and…
SOM Biotech is a clinical-stage drug discovery and development company based in Barcelona, Spain, with an office in the US, focused on repurposing drugs for CNS…
Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally…
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the…
Amyloidosis is a rare disease that manifests itself when amyloid protein deposits accumulate in the body's organs and tissues, ultimately causing organ failure if…